Physician profile
William Frederick Mayers
NPI 1306200225
$4,620.15
in general payments reported to CMS, 2019-2025
21 companies · $843 in 2025
The $843 reported for 2025 was more than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $246 · 2021: $935 · 2022: $368 · 2023: $1,054 · 2024: $1,174 · 2025: $843.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,071.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,071.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,340.81 | 2021-2025 | Proclaim, Eterna, Octrode |
| Boston Scientific Corporation | $833.40 | 2020-2025 | Intracept, General - Pain Management, Superion Indirect Decompression System |
| Medtronic, INC. | $414.06 | 2021-2025 | Intellis Adaptivestim, Inceptiv, Vanta Adaptivestim |
| Painteq LLC | $323.83 | 2021-2024 | Painteq |
| Relievant Medsystems, INC. | $251.84 | 2022-2023 | Intracept |
| Abbvie INC. | $247.76 | 2023-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $189.31 | 2022-2025 | Relistor, Trulance |
| Valinor Pharma, LLC | $153.40 | 2023-2025 | Movantik |
| Saluda Medical Americas, INC. | $146.28 | 2023-2025 | Evoke, Evoke Scs |
| Vertex Pharmaceuticals Incorporated | $135.83 | 2025 | |
| Nevro Corp. | $117.66 | 2020-2024 | Senza |
| Spinal Simplicity, LLC | $112.55 | 2022-2025 | Ha Minuteman G3-R |
| Medtronic USA, INC. | $90.88 | 2020 | |
| Vertos Medical, INC. | $62.65 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $45.91 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $42.98 | 2023 | Tirosint, Licart |
| Biotronik Nro, INC. | $36.08 | 2025 | Prospera |
| Teva Pharmaceuticals USA, INC. | $28.56 | 2021 | |
| Nalu Medical, INC. | $16.24 | 2024 | Nalu Neurostimulation System |
| Spr Therapeutics, INC | $15.44 | 2024 | Sprint Pns System |
| Amneal Pharmaceuticals LLC | $14.68 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Mayers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.